{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:14:19Z","timestamp":1758759259997,"version":"3.44.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>International guidelines for <jats:italic>Staphylococcus aureus<\/jats:italic> vertebral osteomyelitis recommend 6 weeks of treatment, including oral follow-up using antibiotics with high bioavailability such as a fluoroquinolone\/rifampicin combination. Oral flucloxacillin is not recommended due to low bioavailability and scarce evidence. However, flucloxacillin as oral follow-up treatment is common practice in Sweden based on favourable clinical experience, good tolerability, few interactions, and low ecological impact. Our aim was to review a single-centre experience of <jats:italic>S. aureus<\/jats:italic> vertebral osteomyelitis, with focus on flucloxacillin treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A single-centre retrospective cohort of patients with <jats:italic>Staphylococcus aureus<\/jats:italic> vertebral osteomyelitis (<jats:italic>n<\/jats:italic>\u2009=\u200940) was identified between 2010 and 2016. Patients were further stratified by antibiotic treatment strategy with focus on oral flucloxacillin therapy (<jats:italic>n<\/jats:italic>\u2009=\u200924). Primary outcomes were relapse or death within 12 months of treatment initiation, and antibiotic-related adverse effects during treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Methicillin-susceptible <jats:italic>S. aureus<\/jats:italic> (MSSA) caused 38 of the infections (95%), and five patients (13%) died, all in-hospital. Flucloxacillin was used for at least 75% of the oral treatment duration in 24 patients (60%). Median antibiotic treatment duration among these patients was 125.5 days (IQR 95\u2013182), 109 days (IQR 76\u2013149) of which comprised oral antibiotics. There were two relapses and two deaths among the patients treated predominantly with flucloxacillin, resulting in a composite clinical cure rate of 83% (20 of 24).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Prolonged oral flucloxacillin administration could be a potential treatment option for MSSA vertebral osteomyelitis. A prospective study of optimal treatment duration and dosing strategies for flucloxacillin in vertebral osteomyelitis is warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10096-025-05176-8","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T06:58:35Z","timestamp":1748415515000},"page":"2077-2084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Staphylococcus aureus vertebral osteomyelitis: a single-centre retrospective cohort study with focus on oral flucloxacillin follow-up"],"prefix":"10.1007","volume":"44","author":[{"given":"Johan","family":"Wern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5939-2932","authenticated-orcid":false,"given":"Bo","family":"S\u00f6derquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-9274","authenticated-orcid":false,"given":"Staffan","family":"Tevell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"5176_CR1","doi-asserted-by":"publisher","unstructured":"Lacasse M, Derolez S, Bonnet E, Amelot A, Bouyer B, Carlier R, Coiffier G, Cottier JP, Dinh A, Maldonado I, Paycha F, Ziza JM, Bemer P L. Bernard and G. Review (2023) 2022 SPILF - Clinical practice G.idelines for the diagnosis and treatment of disco-vertebral infection in adults. Infect Dis now 53 (3):104647. https:\/\/doi.org\/10.1016\/j.idnow.2023.01.007","DOI":"10.1016\/j.idnow.2023.01.007"},{"key":"5176_CR2","doi-asserted-by":"publisher","unstructured":"Joerger AK, Albrecht C, Lange N, Meyer B, Wostrack M (2023) In-Hospital mortality from spondylodiscitis: insights from a Single-Center retrospective study. J Clin Med 12(23). https:\/\/doi.org\/10.3390\/jcm12237228","DOI":"10.3390\/jcm12237228"},{"issue":"1","key":"5176_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12879-023-08946-x","volume":"24","author":"MM Hijazi","year":"2024","unstructured":"Hijazi MM, Siepmann T, El-Battrawy I, Schrottner P, Podlesek D, Schackert G, Juratli TA, Eyupoglu IY, Filis A (2024) The importance of the bacterial spectrum in the clinical diagnostics and management of patients with spontaneous pyogenic spondylodiscitis and isolated spinal epidural empyema: a 20-year cohort study at a single spine center. BMC Infect Dis 24(1):39. https:\/\/doi.org\/10.1186\/s12879-023-08946-x","journal-title":"BMC Infect Dis"},{"key":"5176_CR4","doi-asserted-by":"publisher","unstructured":"Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM 3rd, Petermann GW, Osmon DR (2015) Executive summary: 2015 infectious diseases society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 61(6):859\u2013863. https:\/\/doi.org\/10.1093\/cid\/civ633","DOI":"10.1093\/cid\/civ633"},{"issue":"1","key":"5176_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/cid\/ciad560","volume":"78","author":"SE Zein","year":"2024","unstructured":"Zein SE, Berbari EF, Passerini M, Petri F, Maamari J, Murad MH, Sendi P, Tande AJ (2024) Rifampin based therapy for patients with Staphylococcus aureus native vertebral osteomyelitis: A systematic review and Meta-analysis. Clin Infect Dis 78(1):40\u201347. https:\/\/doi.org\/10.1093\/cid\/ciad560","journal-title":"Clin Infect Dis"},{"key":"5176_CR6","doi-asserted-by":"publisher","unstructured":"Bongers S, Hellebrekers P, Leenen LPH, Koenderman L, Hietbrink F (2019) Intracellular penetration and effects of antibiotics on Staphylococcus aureus inside human neutrophils: A comprehensive review. Antibiot (Basel) 8(2). https:\/\/doi.org\/10.3390\/antibiotics8020054","DOI":"10.3390\/antibiotics8020054"},{"issue":"1","key":"5176_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/j.1552-4604.1995.tb04742.x","volume":"35","author":"J Gath","year":"1995","unstructured":"Gath J, Charles B, Sampson J, Smithurst B (1995) Pharmacokinetics and bioavailability of Flucloxacillin in elderly hospitalized patients. J Clin Pharmacol 35(1):31\u201336. https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04742.x","journal-title":"J Clin Pharmacol"},{"key":"5176_CR8","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2147\/DDDT.S138888","volume":"11","author":"F Greimel","year":"2017","unstructured":"Greimel F, Scheuerer C, Gessner A, Simon M, Kalteis T, Grifka J, Benditz A, Springorum HR, Schaumburger J (2017) Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with Moxifloxacin, Flucloxacillin, Rifampin, and combination therapy: an animal study. Drug Des Devel Ther 11:1729\u20131736. https:\/\/doi.org\/10.2147\/DDDT.S138888","journal-title":"Drug Des Devel Ther"},{"key":"5176_CR9","doi-asserted-by":"publisher","unstructured":"Preiss H, Kriechling P, Montrasio G, Huber T, Janssen I, Moldovan A, Lipsky B, Uckay I (2019) Oral flucloxacillin for treating osteomyelitis: A narrative review of clinical practice. J Bone Jt Infect. 2020;5(1):16\u201324. https:\/\/doi.org\/10.7150\/jbji.40667","DOI":"10.7150\/jbji.40667"},{"issue":"3","key":"5176_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/inf.1969.1.issue-3.07","volume":"1","author":"SA Hedstrom","year":"1969","unstructured":"Hedstrom SA (1969) General and local antibiotic treatment of chronic osteomyelitis. Scand J Infect Dis 1(3):175\u2013180","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"5176_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/inf.1974.6.issue-1.06","volume":"6","author":"SA Hedstrom","year":"1974","unstructured":"Hedstrom SA (1974) The prognosis of chronic Staphylococcal osteomyelitis after long-term antibiotic treatment. Scand J Infect Dis 6(1):33\u201338. https:\/\/doi.org\/10.3109\/inf.1974.6.issue-1.06","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"5176_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/inf.1980.12.issue-3.10","volume":"12","author":"SA Hedstrom","year":"1980","unstructured":"Hedstrom SA, Kahlmeter G (1980) Dicloxacillin and Flucloxacillin twice daily with probenecid in Staphylococcal infections. A clinical and Pharmakokinetic evaluation. Scand J Infect Dis 12(3):221\u2013225. https:\/\/doi.org\/10.3109\/inf.1980.12.issue-3.10","journal-title":"Scand J Infect Dis"},{"key":"5176_CR13","unstructured":"Tevell S, Christensson B, Nilsdotter-Augustinsson A, Ryd\u00e9n C, Ryding U, S\u00f6derquist B, \u00c5kerlund B (2023) Svenska Infektionsl\u00e4karf\u00f6reningens v\u00e5rdprogram f\u00f6r led- och skelettinfektioner. 4th edition. www.infektion.net"},{"issue":"1","key":"5176_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7150\/jbji.42852","volume":"5","author":"S Tevell","year":"2020","unstructured":"Tevell S, Christensson B (2020) Oral Flucloxacillin for Staphylococcal osteomyelitis: obsolete or underused?? J Bone Jt Infect 5(1):25\u201327. https:\/\/doi.org\/10.7150\/jbji.42852","journal-title":"J Bone Jt Infect"},{"issue":"10","key":"5176_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/cid\/ciw098","volume":"62","author":"KH Park","year":"2016","unstructured":"Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, Lee YM, Chong YP, Kim SH, Lee SO, Choi SH, Bae IG, Kim YS, Woo JH, Lee MS (2016) Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at low risk and high risk of recurrence. Clin Infect Dis 62(10):1262\u20131269. https:\/\/doi.org\/10.1093\/cid\/ciw098","journal-title":"Clin Infect Dis"},{"issue":"9971","key":"5176_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","volume":"385","author":"L Bernard","year":"2015","unstructured":"Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, Therby A, Bouhour D, Denes E, Debard A, Chirouze C, Fevre K, Dupon M, Aegerter P, Mulleman D (2015) Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet 385(9971):875\u2013882. https:\/\/doi.org\/10.1016\/S0140-6736(14)61233-2","journal-title":"Lancet"},{"issue":"7","key":"5176_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/00365540110026566","volume":"33","author":"M Beronius","year":"2001","unstructured":"Beronius M, Bergman B, Andersson R (2001) Vertebral osteomyelitis in Goteborg, Sweden: a retrospective study of patients during 1990-95. Scand J Infect Dis 33(7):527\u2013532. https:\/\/doi.org\/10.1080\/00365540110026566","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"5176_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12879-023-08266-0","volume":"23","author":"N Okumura","year":"2023","unstructured":"Okumura N, Hayakawa K, Yamamoto K, Yamada G, Mezaki K, Ohmagari N (2023) Effectiveness of oral cephalexin in antibiotic-course completion for methicillin-susceptible Staphylococcus aureus-induced bacteremic vertebral osteomyelitis. BMC Infect Dis 23(1):307. https:\/\/doi.org\/10.1186\/s12879-023-08266-0","journal-title":"BMC Infect Dis"},{"issue":"3","key":"5176_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3947\/ic.2019.51.3.284","volume":"51","author":"WS Oh","year":"2019","unstructured":"Oh WS, Moon C, Chung JW, Choo EJ, Kwak YG, Kim SH, Ryu SY, Park SY, Kim BN (2019) Antibiotic treatment of vertebral osteomyelitis caused by Methicillin-Susceptible Staphylococcus aureus: A focus on the use of oral beta-lactams. Infect Chemother 51(3):284\u2013294. https:\/\/doi.org\/10.3947\/ic.2019.51.3.284","journal-title":"Infect Chemother"},{"issue":"10","key":"5176_CR20","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/cid\/ciw100","volume":"62","author":"O Murillo","year":"2016","unstructured":"Murillo O, Lora-Tamayo J (2016) Editorial commentary: pyogenic vertebral osteomyelitis and antimicrobial therapy: it\u2019s not just the length, but also the choice. Clin Infect Dis 62(10):1270\u20131271. https:\/\/doi.org\/10.1093\/cid\/ciw100","journal-title":"Clin Infect Dis"},{"issue":"2","key":"5176_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/cid\/ciad168","volume":"77","author":"M Bock","year":"2023","unstructured":"Bock M, Theut AM, van Hasselt JGC, Wang H, Fuursted K, Hoiby N, Lerche CJ, Ihlemann N, Gill S, Christiansen U, Nielsen HL, Lemming L, Elming H, Povlsen JA, Bruun NE, Hofsten D, Fosbol EL, Kober L, Schultz M, Pries-Heje MM, Kristensen JH, Christensen JJ, Rosenvinge FS, Pedersen CT, Helweg-Larsen J, Tonder N, Iversen K, Bundgaard H, Moser C (2023) Attainment of target antibiotic levels by oral treatment of Left-Sided infective endocarditis: A POET substudy. Clin Infect Dis 77(2):242\u2013251. https:\/\/doi.org\/10.1093\/cid\/ciad168","journal-title":"Clin Infect Dis"},{"issue":"7","key":"5176_CR22","first-page":"255","volume":"77","author":"AC Dijkmans","year":"2019","unstructured":"Dijkmans AC, Kweekel DM, Balmforth C, van Esdonk MJ, van Dissel JT, Burggraaf J, Kamerling IMC (2019) The simplified oral Flucloxacillin absorption test: an accurate method to identify patients with inadequate oral Flucloxacillin absorption. Neth J Med 77(7):255\u2013260","journal-title":"Neth J Med"},{"issue":"3","key":"5176_CR23","doi-asserted-by":"publisher","first-page":"446e441","DOI":"10.1016\/j.cmi.2021.06.039","volume":"28","author":"E Wallenburg","year":"2022","unstructured":"Wallenburg E, Bruggemann RJM, Roberts JA, Jager NGL, Ulldemolins M, Wilkes S, Schouten J, Chin PKL, Ter Heine R (2022) A meta-analysis of protein binding of Flucloxacillin in healthy volunteers and hospitalized patients. Clin Microbiol Infect 28(3):446e441\u2013446e447. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.039","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"5176_CR24","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/jac\/dkae207","volume":"79","author":"L Hermann","year":"2024","unstructured":"Hermann L, Schoning V, Drager S, Rentsch K, Moser S, Gurtler N, Sendi P, Osthoff M, Hammann F (2024) Population pharmacokinetics of Flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection. J Antimicrob Chemother 79(8):2031\u20132039. https:\/\/doi.org\/10.1093\/jac\/dkae207","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"5176_CR25","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1093\/jac\/dkab314","volume":"76","author":"E Wallenburg","year":"2021","unstructured":"Wallenburg E, Ter Heine R, de Lange DW, van Leeuwen H, Schouten JA, Ten Oever J, Kolwijck E, Burger DM, Pickkers P, Gieling EM, de Maat MM, Frenzel T, Bruggemann RJ (2021) High unbound Flucloxacillin fraction in critically ill patients. J Antimicrob Chemother 76(12):3220\u20133228. https:\/\/doi.org\/10.1093\/jac\/dkab314","journal-title":"J Antimicrob Chemother"},{"key":"5176_CR26","doi-asserted-by":"publisher","unstructured":"Roelofsen EE, de Winter BCM, van der Spek H, Snijders S, Koch BCP, van den Berg S, Muller AE (2022) Pharmacodynamics of Flucloxacillin in a neutropenic murine thigh infection model: A piece of the puzzle towards Evidence-Based dosing. Antibiot (Basel) 11(8). https:\/\/doi.org\/10.3390\/antibiotics11081049","DOI":"10.3390\/antibiotics11081049"},{"issue":"1","key":"5176_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jinf.2019.09.004","volume":"80","author":"RJ Everts","year":"2020","unstructured":"Everts RJ, Begg R, Gardiner SJ, Zhang M, Turnidge J, Chambers ST, Begg EJ (2020) Probenecid and food effects on Flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers. J Infect 80(1):42\u201353. https:\/\/doi.org\/10.1016\/j.jinf.2019.09.004","journal-title":"J Infect"},{"issue":"6","key":"5176_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/s0277-9536(98)00405-5","volume":"48","author":"EE Roughead","year":"1999","unstructured":"Roughead EE, Gilbert AL, Primrose JG (1999) Improving drug use: a case study of events which led to changes in use of Flucloxacillin in Australia. Soc Sci Med 48(6):845\u2013853. https:\/\/doi.org\/10.1016\/s0277-9536(98)00405-5","journal-title":"Soc Sci Med"},{"issue":"9","key":"5176_CR29","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/jac\/dkx183","volume":"72","author":"K Wing","year":"2017","unstructured":"Wing K, Bhaskaran K, Pealing L, Root A, Smeeth L, van Staa TP, Klungel OH, Reynolds RF, Douglas I (2017) Quantification of the risk of liver injury associated with Flucloxacillin: a UK population-based cohort study. J Antimicrob Chemother 72(9):2636\u20132646. https:\/\/doi.org\/10.1093\/jac\/dkx183","journal-title":"J Antimicrob Chemother"},{"key":"5176_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/DHPS.S178394","volume":"10","author":"M Lindh","year":"2018","unstructured":"Lindh M, Hallberg P, Yue QY, Wadelius M (2018) Clinical factors predicting drug-induced liver injury due to Flucloxacillin. Drug Healthc Patient Saf 10:95\u2013101. https:\/\/doi.org\/10.2147\/DHPS.S178394","journal-title":"Drug Healthc Patient Saf"},{"key":"5176_CR31","doi-asserted-by":"publisher","unstructured":"Soldevila-Boixader L, Murillo O, Waibel FWA, Huber T, Schoni M, Lalji R, Uckay I (2023) The epidemiology of Antibiotic-Related adverse events in the treatment of diabetic foot infections: A narrative review of the literature. Antibiot (Basel) 12(4). https:\/\/doi.org\/10.3390\/antibiotics12040774","DOI":"10.3390\/antibiotics12040774"},{"issue":"2","key":"5176_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","volume":"90","author":"PA Aristoff","year":"2010","unstructured":"Aristoff PA, Garcia GA, Kirchhoff PD, Showalter HD (2010) Rifamycins-obstacles and opportunities. Tuberculosis (Edinb) 90(2):94\u2013118. https:\/\/doi.org\/10.1016\/j.tube.2010.02.001","journal-title":"Tuberculosis (Edinb)"},{"key":"5176_CR33","doi-asserted-by":"publisher","unstructured":"Miller AC, Arakkal AT, Sewell DK, Segre AM, Tholany J P. M. Polgreen and C. D. C. M.-H. Group (2023) comparison of different antibiotics and the risk for Community-Associated Clostridioides difficile infection: A Case-Control study. Open Forum Infect Dis 10 (8):ofad413. https:\/\/doi.org\/10.1093\/ofid\/ofad413","DOI":"10.1093\/ofid\/ofad413"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05176-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:23:39Z","timestamp":1758720219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05176-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5176"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05176-8","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.S. has been a member of an advisory board at ADVANZ PHARMA, and has also received speaker\u2019s fees from Correvio Pharma Corp and ADVANZ PHARMA. All other authors: none to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declaration"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}